GHK-Cu vs Matrixyl.

GHK-Cu is the copper(II) complex of GHK, a naturally occurring human tripeptide with the sequence glycyl-L-histidyl-L-lysine. GHK was first isolated from human plasma by Loren Pickart in the early 1970s and also occurs in saliva and urine; it binds copper ions with high affinity to form the violet-colored GHK-Cu complex. The free peptide sequence is embedded within the alpha-2 chain of type I collagen, and it is thought to be liberated during tissue injury, making it a candidate endogenous signal of tissue damage and repair. It is best known as a cosmetic ingredient and a widely studied "copper peptide."

Matrixyl is the trade name (Sederma/Croda) for palmitoyl pentapeptide-4, also written pal-KTTKS or palmitoyl-Lys-Thr-Thr-Lys-Ser. It is a synthetic cosmetic peptide consisting of a five-amino-acid fragment of type I procollagen (the KTTKS sequence) conjugated to palmitic acid, a fatty-acid tail added to improve lipophilicity and skin penetration. It is sold as a topical anti-aging skincare active, not as a drug or an injectable; the related blend "Matrixyl 3000" pairs a different peptide (palmitoyl tripeptide-1 / pal-GHK) with palmitoyl tetrapeptide-7.

GHK is a copper-coordinating molecule: the glycine amino terminus, the histidine imidazole, and a deprotonated peptide nitrogen form a square-planar Cu(II) chelate, a geometry confirmed by X-ray and solution-structure studies, allowing GHK to shuttle copper to and from cells and to modulate copper's redox chemistry. Beyond copper transport, GHK-Cu has been reported to stimulate fibroblast synthesis of collagen, elastin, glycosaminoglycans, and proteoglycans while modulating matrix metalloproteinases, consistent with a role in dermal remodeling. Bioinformatic analysis using the Broad Institute Connectivity Map found that GHK alters the expression of a large fraction of assayed human genes in cultured cells (upregulating some and suppressing others), including genes tied to antioxidant defense, anti-inflammatory signaling, DNA repair, and tissue regeneration. It has also shown antioxidant behavior in vitro, including blocking copper-dependent oxidation of low-density lipoprotein.

KTTKS is a sub-fragment of the C-terminal propeptide of type I collagen. Liberation of such procollagen fragments during matrix turnover is thought to act as a feedback signal that up-regulates new extracellular matrix synthesis, so the peptide is described as a "matrikine" or signal peptide rather than a hormone or growth factor. In cultured human dermal fibroblasts, KTTKS and pal-KTTKS have been reported to stimulate production of type I and III collagen, fibronectin, and glycosaminoglycans. The palmitoyl tail is non-functional pharmacologically; its role is to make the otherwise hydrophilic peptide lipophilic enough to cross the stratum corneum. The peptide does not relax muscle (it is not a "Botox-like" neuromodulator, unlike acetyl hexapeptide-8/Argireline).

The strongest human evidence is cosmetic/dermatologic: small topical studies of GHK-Cu-containing creams have reported improvements in skin appearance, density, and wrinkles, but these are generally short, small, and often industry-adjacent rather than large randomized therapeutic trials. Much of the mechanistic case rests on in vitro and animal work (fibroblast cultures, rodent and rabbit wound-healing models, and rat nerve-regeneration experiments), plus gene-expression analyses (Pickart & Margolina, Int J Mol Sci 2018; Pickart et al., BioMed Res Int 2015). A notable bioinformatic finding is that GHK was computationally identified, via Connectivity Map screening of a human COPD lung gene signature, as a compound predicted to reverse that disease-associated expression pattern (Meiners & Eickelberg, Genome Medicine 2012), but this was a transcriptomic prediction, not a clinical trial, and GHK was not administered to patients. There are no large controlled human trials supporting injected/systemic GHK-Cu for anti-aging, organ repair, or the regenerative claims often made online; that gap between mechanistic plausibility and proven clinical benefit is wide.

Human evidence comes from cosmetic split-face/vehicle-controlled topical trials, not drug-grade efficacy programs. The most cited is Robinson et al. (Int J Cosmet Sci, 2005), a 12-week double-blind, vehicle-controlled, split-face study in 93 women (ages 35-55) where a moisturizer with 3 ppm pal-KTTKS gave statistically significant reductions in fine lines/wrinkles versus the same vehicle by quantitative image analysis, expert grading, and self-assessment, and was well tolerated. A daily-moisturizer study published in JAAD (2004) similarly reported improvement in the appearance of aging skin. A 2023 double-blind RCT in the Journal of Clinical and Aesthetic Dermatology compared palmitoyl pentapeptide-4 cream with acetyl hexapeptide-3 for crow's feet. Importantly, headline figures often quoted in marketing (e.g. "stimulates collagen by ~350%" or large fibronectin increases) derive from in-vitro fibroblast assays, not human skin, and effect sizes in human trials are modest; independent head-to-head data versus retinoids remain limited.

In topical cosmetic use GHK-Cu has a long track record and is generally well tolerated, with the main reported issues being local irritation, redness, or contact sensitivity in some users. The safety of injected or systemic GHK-Cu in humans is not established by rigorous clinical study, and because the molecule carries copper, concerns about copper loading and pro-oxidant copper redox chemistry are biologically plausible and not well characterized for non-topical use. Purity, sterility, and actual copper content of research-grade or compounded products are unverified and vary by supplier. Overall, human safety data outside cosmetic topical contexts is thin, and unknowns dominate.

In the published topical trials pal-KTTKS was well tolerated, with low rates of irritation, erythema, or sensitization and a generally favorable cosmetic safety profile, one reason it is often positioned as a gentler alternative to retinoids. The Cosmetic Ingredient Review and EU cosmetic frameworks treat palmitoyl oligopeptides as safe for topical use at the low concentrations used in finished products. That said, safety data are specific to topical, leave-on cosmetic use at trace concentrations; there is no established safety profile for injected, oral, or high-concentration use, and such routes are not a recognized use of this ingredient. As with any topical, individual allergic or irritant contact reactions are possible, and pregnancy/long-term systemic data are essentially absent because systemic exposure from topical use is expected to be negligible.

GHK-Cu is not an FDA-approved drug; it is used as a cosmetic skincare ingredient (where cosmetic ingredients are not FDA pre-approved) and is otherwise sold for research/investigational purposes. It is not an approved therapeutic for wound healing, anti-aging, or any systemic indication, and it is not currently a WADA-prohibited substance.

Matrixyl/palmitoyl pentapeptide-4 is regulated as a cosmetic ingredient, not an FDA-approved drug; it makes appearance ("cosmetic") claims rather than treatment claims and has not undergone FDA drug approval. It is widely used in over-the-counter skincare in the US, EU, and elsewhere, and is not a controlled substance or a WADA-prohibited compound.